Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge(Unknown), A. Q. Adeleke, SJ Hauske(Boehringer Ingelheim (Germany)), Karl Wallendszus, Julie Green, Natalie Staplin(Medical Research Council), David Z.I. Cherney(Sunnybrook Health Science Centre), Colin Baigent(University of Oxford), Jonathan Emberson(University of Oxford), Christoph Wanner(University of Würzburg), Masaomi Nangaku(The University of Tokyo), David Preiss(Medical Research Council), Takashi Kadowaki(The University of Tokyo), Adeera Levin(Providence Health Care), Katherine R. Tuttle(University of Washington), Xavier Rosselló(University College London), Dominik Steubl(Boehringer Ingelheim (Germany)), Nader G. Abraham(University of Toledo), Rajat Deo, WG Herrington(Boehringer Ingelheim (Germany)), Emily Sammons, Rizna Abdul Cader(Boehringer Ingelheim (Germany)), MZ Abdul Wahab, AK Cheung, Talal Abdulsamad, Martin Landray, Roberto Pontremoli(Ospedale Policlinico San Martino), Daisy Massey, Susanne Brenner, Shinichi Goto, Aldo P. Maggioni, Richard Haynes, Riaz Rahman, S Abat, P Achiri, J Li(Agency for Science, Technology and Research), Wenjun Liu(Macau University of Science and Technology), Zhihong Liu(Nanjing General Hospital of Nanjing Military Command), NK Abdullah, Dandan Zhu, MI Abdul Hafidz, AJ Roddick, LS Hooi, W. Grant Stevens, Sarah Acheampong, KJ Mayne, SYA Ng, Masanori Abe(Japanese Society for Dialysis Therapy), JA Acosta, Michael Hill(University of Ottawa)
Cited by 107
Related Papers
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k